While Tarsus Pharmaceuticals Inc has underperformed by -0.04%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TARS rose by 217.78%, with highs and lows ranging from $52.99 to $15.60, whereas the simple moving average jumped by 49.00% in the last 200 days.
On November 20, 2023, Goldman started tracking Tarsus Pharmaceuticals Inc (NASDAQ: TARS) recommending Neutral. A report published by William Blair on July 18, 2023, Initiated its previous ‘Outperform’ rating for TARS. Barclays Initiated an Overweight rating on August 01, 2022, and assigned a price target of $40. H.C. Wainwright initiated its ‘Buy’ rating for TARS, as published in its report on December 21, 2021. Oppenheimer’s report from November 23, 2021 suggests a price prediction of $55 for TARS shares, giving the stock a ‘Outperform’ rating. Raymond James also rated the stock as ‘Strong Buy’.
Analysis of Tarsus Pharmaceuticals Inc (TARS)
Further, the quarter-over-quarter increase in sales is 2471.78%, showing a positive trend in the upcoming months.
To gain a thorough understanding of Tarsus Pharmaceuticals Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -59.56% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 5.38, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and TARS is recording an average volume of 742.42K. On a monthly basis, the volatility of the stock is set at 6.03%, whereas on a weekly basis, it is put at 4.37%, with a gain of 4.30% over the past seven days. Furthermore, long-term investors anticipate a median target price of $65.00, showing growth from the present price of $50.40, which can serve as yet another indication of whether TARS is worth investing in or should be passed over.
How Do You Analyze Tarsus Pharmaceuticals Inc Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As opposed to executive stock, institutional ownership accounts for 109.14% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
TARS shares are owned by institutional investors to the tune of 109.14% at present.
